Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prolight Diagnostics ABLTS:0G5I 31 WACC % is 6.16% as of Aug. 02, 2026, which is 27% below its 10-year median of 8.47. GuruFocus rates LTS:0G5I with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 863 Medical Devices & Instruments companies, Prolight Diagnostics AB ranks better than 53.3% on this metric.
As of today (2026-08-02), Prolight Diagnostics AB's weighted average cost of capital is 6.16%%. Prolight Diagnostics AB's ROIC % is -26.83% (calculated using TTM income statement data).
Prolight Diagnostics AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
Prolight Diagnostics AB (LTS:0G5I) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Prolight Diagnostics AB's weighted average cost of capital is 6.16%%. Prolight Diagnostics AB's ROIC % is -26.83% (calculated using TTM income statement data).
Prolight Diagnostics AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prolight Diagnostics AB WACC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's WACC % distribution charts can be found below:
* The bar in red indicates where Prolight Diagnostics AB's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Prolight Diagnostics AB's market capitalization (E) is kr215.602 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Prolight Diagnostics AB's latest one-year quarterly average Book Value of Debt (D) is kr0 Mil.
a) weight of equity = E / (E + D) = 215.602 / (215.602 + 0) = 1
b) weight of debt = D / (E + D) = 0 / (215.602 + 0) = 0
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 2.7807%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Prolight Diagnostics AB's beta is 0.5632.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 2.7807% + 0.5632 * 6% = 6.1599%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Prolight Diagnostics AB's interest expense (positive number) was kr0.323 Mil. Its total Book Value of Debt (D) is kr0 Mil.
Cost of Debt = 0.323 / 0 = %.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -3.372 / -52.534 = 6.42%.
Prolight Diagnostics AB's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC
=
E / (E + D)
*
Cost of Equity
+
D / (E + D)
*
Cost of Debt
*
(1 - Tax Rate)
=
1
*
6.1599%
+
0
*
%
*
(1 - 6.42%)
=
6.16%
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prolight Diagnostics AB (LTS:0G5I) has a WACC % of 6.16% as of Aug. 02, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Prolight Diagnostics AB and its competitors. This is 27% below median its historical median of 8.47. Over the past decade, Prolight Diagnostics AB's WACC % has ranged from 6.07 to 18.48. According to the industry distribution chart, Prolight Diagnostics AB ranks #403 out of 863 companies in the Medical Devices & Instruments industry, placing it in the top 46.7%.
Is Prolight Diagnostics AB's WACC % too high?
Prolight Diagnostics AB's current WACC % of 6.16% is 27% below median its 10-year median of 8.47. Over the past 10 years, this metric has ranged from a low of 6.07 to a high of 18.48. The Medical Devices & Instruments industry median WACC % is 9.20. Prolight Diagnostics AB's value of 6.16% is 33% below this industry median. Based on the distribution chart, Prolight Diagnostics AB ranks #403 out of 863 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Prolight Diagnostics AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's WACC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prolight Diagnostics AB ranks #403 out of 863 companies for WACC %. This puts Prolight Diagnostics AB in the upper half of its industry. The industry median WACC % is 9.20. Prolight Diagnostics AB's value of 6.16% is 33% below this benchmark. Historically, Prolight Diagnostics AB's own WACC % has ranged from 6.07 to 18.48 over the past decade. While the company's 10-year median is 8.47 vs. the industry median of 9.20, Prolight Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Medical Devices & Instruments company?
The median WACC % among Medical Devices & Instruments companies is 9.20, based on 863 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prolight Diagnostics AB's current WACC % of 6.16% is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Prolight Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median WACC % is 9.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prolight Diagnostics AB's current WACC % is 6.16%, which is 27% below median its own 10-year median of 8.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (LTS:0G5I) has a current WACC % of 6.16%. The current WACC % is 6.16%, which is 27% below median its 10-year median of 8.47 and 33% below the Medical Devices & Instruments industry median of 9.20. Prolight Diagnostics AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Prolight Diagnostics AB (LTS:0G5I), the current WACC % is 6.16% as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
31GF Score
Get the complete analysis for LTS:0G5I
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0G5I has been successfully added to your 
